BridgeMD
A phase 2a study of CR9114 in healthy adult participants
EU CTIS ID: 2023-505020-57-00
What this study is testing
To determine the effect of CR9114 on reducing the incidence of MMID. To determine the safety and tolerability of CR9114.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female, between 18 and 55 years old at screening, extremes included.
- Body Mass Index (BMI) within normal range: 19.0 ≤ BMI ≤ 30.0 kg/m2 at screening and with a minimum weight of 50.0 kg.
- Healthy in the investigator’s clinical judgment, as confirmed by medical history, physical examination, vital signs, 12-lead ECG and laboratory assessments performed at screening and/or pre-randomization.
- Negative hepatitis panel including hepatitis B Virus surface antigen (HBsAg), anti-hepatitis B virus core (HBc) Ab, and anti-hepatitis C virus (HCV) Abs (with reflex HCV RNA, ie, positive for HCV Abs is allowed if negative for HCV RNA) and negative human immunodeficiency virus (HIV) Type 1 and Type 2 Ab screens at screening.
You likely can't join if
- Any reason that would limit the participant’s ability to complete the trial or might interfere with the primary trial objectives for safety of the trial participant based on the opinion of the investigator.
- History of severe local or systemic reactogenicity to any medication (eg, anaphylaxis, respiratory difficulties, angioedema).
- Known allergy or hypersensitivity to any component of IP or viral challenge agent, including known or suspected egg allergies.
- Presence of nasal polyps or significant nasal abnormalities or facial muscular paralysis (eg, Bell’s Palsy) and/or history of chronic sinusitis or chronic use (at least 14 days in the 2 months prior to screening) of nasally applied medications.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.